Drug
Salmeterol Fluticasone
Salmeterol Fluticasone is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 42 (66.7%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_4
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
NCT04503460
completedphase_3
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01908140
completedphase_4
Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma
NCT01255579
Clinical Trials (3)
Showing 3 of 3 trials
NCT04503460Phase 4
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
NCT01908140Phase 3
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01255579Phase 4
Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3